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MUC5AC, a major gel-forming mucin expressed in the lungs, is se-
creted at increased rates in response to infectious agents, implying
thatmucins exert a protective role against inhaled pathogens. How-
ever, epidemiological and pathological studies suggest that exces-
sive mucin secretion causes airways obstruction and inflammation.
To determine whether increasedMUC5AC secretion alone produces
airway obstruction and/or inflammation, we generated a mouse
model overexpressing Muc5ac mRNA ∼20-fold in the lungs, using
the rCCSP promoter. The Muc5ac cDNA was cloned from mouse
lungs and tagged internally with GFP. Bronchoalveolar lavage fluid
(BALF) analysis demonstrated an approximate 18-fold increase in
Muc5ac protein, which formed high-molecular-weight polymers.
Histopathological studies and cell counts revealed no airway mucus
obstruction or inflammation in the lungs of Muc5ac-transgenic
(Muc5ac-Tg) mice. Mucus clearance was preserved, implying that
the excess Muc5ac secretion produced an “expanded” rather than
more concentrated mucus layer, a prediction confirmed by electron
microscopy. To test whether the larger mucus barrier conferred in-
creased protection against pathogens, Muc5ac-Tg animals were
challengedwith PR8/H1N1 influenza viruses and showed significant
decreases in infection and neutrophilic responses. Plaque assay
experiments demonstrated that Muc5ac-Tg BALF and purified
Muc5ac reduced infection, likely via binding to α2,3-linked sialic
acids, consistent with influenza protection in vivo. In conclusion,
the normal mucus transport and absence of a pulmonary phenotype
in Muc5ac-Tg mice suggests that mucin hypersecretion alone is not
sufficient to trigger luminal mucus plugging or airways inflamma-
tion/goblet cell hyperplasia. In contrast, increased Muc5ac secretion
appears to exhibit a protective role against influenza infection.
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Airway mucus is a complex hydrophilic gel composed of gel-forming mucins, globular proteins, salt, and water. The gel-
like properties of interpenetrating mucins serve to trap and clear
inhaled pathogens, protecting the lungs against infection. Of
the gel-forming mucins, only two, MUC5AC and MUC5B, are
expressed in the lungs (1). Mucin protein cores of MUC5AC and
MUC5B are decorated by a diverse repertoire of carbohydrate
moieties, including sialic acid and sulfate residues, which interact
with inhaled particulates, including pathogens. MUC5B is pri-
marily secreted by submucosal glands, but also by airway goblet
cells (2, 3), and is thought to play mostly a protective role. In
contrast, MUC5AC, which is exclusively produced by goblet cells
(4), has been thought to play more of a pathologic role because of
greatly increased MUC5AC expression with disease states (5–8).
Clearance of mucus is an essential component of the innate
defense required for respiratory health. Normally, a thin mucus
layer on airway surfaces is efficiently transported by coordinated
beating of cilia. Mucin hypersecretion has been speculated to
compromise mucociliary clearance (MCC) and, therefore, a role
for increased mucin secretion has been proposed in the patho-
genesis of airway diseases (9, 10). Indeed, postmortem and airway
biopsy studies support a significant pathophysiologic role for
mucus hypersecretion in airways obstruction and inflammation
observed in severe forms of asthma and chronic obstructive pul-
monary disease (COPD) (11, 12).
Although mucin hypersecretion is associated with chronic lung
diseases, it is unclear whether mucin hypersecretion alone can
produce mucus obstruction and/or inflammation or whether
mucin hypersecretion requires an inflammatory component or
insufficient hydration to produce muco-obstructive disease. In-
deed, it is possible that mucin hypersecretion per se is beneficial
to the host, increasing the capacity to trap and clear inhaled
foreign materials. Animal models of mucin hypersecretion, e.g.,
ovalbumin-sensitized mice (13) and the βENaC transgenic (14)
mouse models, exhibit muco-obstructive airway disease associ-
ated with inflammatory cell infiltrates but these models have not
permitted dissection of the relative roles for mucin hypersecre-
tion vs. inflammation in disease pathogenesis. The increasing
interest in mucin hypersecretion as a therapeutic target argues
for studies designed to understand the role of mucin hyperse-
cretion in disease pathogenesis.
To distinguish between the possible roles of mucin hyperse-
cretion in augmenting host defense vs. disease promoting muco-
obstructive lung disease, a transgenic mousemodel overexpressing
Muc5ac in murine airways was generated. This model was used to
ask whether mucin hypersecretion alone was sufficient to cause
mucus plugging, drive goblet cell metaplasia, and/or cause airway
inflammation. In parallel, we asked whether increased Muc5ac
secretion provided benefit against inhaled pathogens, using a well-
characterized influenza virus challenge model.
Results
Muc5ac-GFP cDNA Cloning and Expression. Muc5ac, like most se-
creted mucins, possesses a large central domain composed of
variable numbers of tandem repeats (VNTRs), flanked by non-
repeat domains analogous to the von Willebrand factor domains
that are essential for mucin function (Fig. 1A). Because secreted
mucins use their N and C termini for multimerization and di-
merization, respectively, GFP tagging required internal insertion.
The entire Muc5ac cDNA was cloned, and the GFP tag was
inserted immediately 5′ of the VNTR. The fusion product
exhibited a final length of 9.1 kb (Fig. S1) and was placed under
the control of the rat Clara cell secretory protein (rCCSP) pro-
moter. Clara cells possess the entire secretory machinery to en-
sure posttranslational maturation of mucins and populate the
large and small murine airways (15). Consequently, the rCCSP
promoter selectively directs expression in the airways in a mucin-
secretion–competent cell.
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Although 293T cells are not mucin-producing cells, this cell
line was transiently transfected with Muc5ac-GFP cDNA to test
the function of the GFP tag. Sporadic green fluorescent cells
were detected after 24 h (Fig. 1B), which confirmed the proper
insertion and function of GFP. Subsequently, blastocyst injec-
tions to generate transgenic mice overexpressing Muc5ac-GFP
were performed in a C57BL/6 background. Founders were an-
alyzed for mRNA and protein expression. A transgenic line that
showed an approximate 20-fold increase in Muc5ac mRNA ex-
pression by quantitative PCR using whole lung extracts was se-
lected for further study (P < 0.0005) (Fig. 1C).
The expression profile of endogenous Muc5ac and Muc5b was
first analyzed in WT mice, using primers with comparable effi-
ciency (each approaching 2) and normalizing to 18S. The levels
of expression of endogenous Muc5ac were low and similar in
proximal vs. distal airways (Fig. 1D). In contrast, Muc5b was the
dominant secreted mucin in the WT strain but was expressed at
much higher levels proximally than distally. Muc5ac-transgenic
(Muc5ac-Tg) mice overexpressed Muc5ac mRNA by 21.3- and
22.1-fold for distal and proximal regions, respectively. In-
terestingly, mRNA measurements revealed that the levels of
Muc5b transcripts were not affected by Muc5ac overexpression
in either distal or proximal regions. Importantly, these data
demonstrate that total secreted mucin mRNA levels in Muc5ac-
Tg mice were greatly increased in distal airways (mainly due to
expressed transgenic Muc5ac), whereas total secreted mucin
mRNA levels approximately doubled in proximal airways (i.e.,
Muc5ac levels equalled Muc5b levels).
Muc5ac-GFP Secretion and Polymer Formation. We next measured
the levels of Muc5ac protein in transgenic vs. WT lungs and
investigated whether the transgenic Muc5ac protein was secreted
into the airway lumen. To test for proper maturation/assembly of
secreted Muc5ac-GFP, we analyzed unreduced bronchoalveolar
lavage fluid (BALF), using agarose Western blots, HPLC/light
scattering, and CsCl density gradients. Lungs were lavaged and
equal volumes of BALF were analyzed by Western blots, using
GFP and/or specific mucin antibodies. Fig. 2A demonstrates
a ladder-like migration pattern of unreduced Muc5ac-Tg BALF
visualized with a GFP antibody, consistent with the secretion of
high-molecular-weight multimers. Muc5b protein levels were
unaffected by transgene expression (consistent with RNA data;
Fig. 1D). The characteristic Muc5ac ladder pattern (16) con-
firmed proper maturation, secretion, and polymer formation of
the transgene. In addition, Muc5ac-GFP–rich material was col-
lected in the void fraction via HPLC and analyzed by re-
fractometry (light scattering/refractive index) to determine
molecular weight/mass (Mr = 5.1 × 107 g/mol) and radius of gy-
ration/size (Rg = 228 nm), which were comparable to those of
endogenous gel-forming mucins (e.g., Muc5b) (Fig. S2). Consis-
tently, CsCl density gradient analysis confirmed that Muc5ac-
GFP migrated through the gradient, which demonstrated that the
exogenous mucin was multimerized and glycosylated (Fig. S3).
Fig. 2B demonstrates the specificity of a unique polyclonal
anti-murine Muc5ac antibody (UNC294) in reduced BALF. The
merged image shows almost complete overlap between GFP and
Muc5ac antibody signals, with the exception of a small band
detected by the Muc5ac antibody, which may correspond to
a cleaved mucin fragment. The Muc5ac antibody (UNC294) was
then used for protein quantification on BALF after reduction.
Note that Muc5ac signal in WT BALF was barely detectable
(Fig. 2C). However, a distinct Muc5ac signal was detected in
BAL samples collected from WT animals sensitized by ovalbu-
min (OVA) challenges that was ∼10.6-fold stronger than in naive
mice. Signal intensity in Muc5ac-Tg mice was 17.7-fold stronger
than in naive mice and 1.7-fold above that in OVA-challenged
animals (P < 0.05). These data indicate a robust up-regulation
and secretion of Muc5ac protein in the lungs of transgenic mice.
Lung Histology and Pulmonary Inflammation.We next evaluated the
impact of Muc5ac overexpression in the murine lung on histol-
ogy and survival. Muc5ac-Tg mice exhibited the expected Men-
delian distribution of genotypes at birth, indicating that Muc5ac-
GFP overexpression in the lungs had no adverse effect on fetal
development or survival. Postnatal survival reached 96% at 40
d after birth for Muc5ac-Tg mice and was comparable to WT
animal survival (Fig. S4). Growth rates were similar between the
Fig. 1. Muc5ac cloning and expression. Muc5ac cDNA was cloned from
mRNA extracted from mouse lungs. (A) Diagram for Muc5ac peptide
domains and localization of insertion of GFP tag. (B) Native GFP fluorescence
from 293T cells transiently transfected with the CCSP-Muc5ac-GFP plasmid.
(C) Fold increase mRNA expression in the whole lungs of transgenic (Tg)
compared with wild-type (WT) mice. Values are means ± SE (n = 5); *P <
0.0005. (D) Muc5ac and Muc5b mRNA pattern of expression in WT and
Muc5ac-Tg lungs, presented as a fold increase over WT expression in the
distal lung. Proximal samples excluded trachea and submucosal glands.
Values are means ± SE (n = 4); *P < 0.01.
Fig. 2. Mucin Western blots on BAL samples for protein function and
quantification. BAL samples from WT, Tg, and ovalbumin-challenged (OVA)
mice were separated via agarose electrophoresis gel and probed with anti-
bodies, as indicated. Equal amounts of BAL were loaded on each lane.
Fluorescent signal was detected for each gel but can be shown in black and
white to optimize definition. (A) Unreduced BAL samples were analyzed for
GFP migration pattern with anti-GFP antibody (goat) and Muc5b content
with anti-Muc5b antibody (rabbit). (B) Validation of a unique Muc5ac anti-
body (UNC294) on reduced BAL samples. (C) Muc5ac protein quantification
from reduced BALF with integrated signal intensities shown on the bar
graph. Values are means ± SE (n = 3); *P < 0.05.








two genotypes, suggesting that gel-forming mucin overexpression
alone did not increase mortality rates or delay growth in this
animal model (Fig. S4).
Standard lung histopathology revealed only rare alcian blue
periodic acid–Schiff (AB-PAS)–positive cells detected in airway
surfaces of transgenic animals, resembling the histology of WT
animals, and there was no evidence of intraluminal mucus pla-
ques or plugs in Muc5ac-Tg animals (Fig. S4). In sharp contrast,
an OVA-exposed WT mouse exhibits numerous enlarged AB-
PAS–positive cells throughout the lungs, coupled with intra-
luminal mucus plaques.
Airway mucus hyperproduction is typically associated with in-
flammatory cell infiltrates in human lung diseases. Therefore, we
tested whether the Muc5ac-GFP–overexpressing mouse model
exhibited evidence of increased airways inflammation. Total in-
flammatory cell counts from BAL revealed no differences in the
total number of cells in Muc5ac-Tg mice compared with control
littermates (Fig. S5A). The majority of cells in BALF in both
genotypes were macrophages with occasional neutrophils, eosi-
nophils, or lymphocytes (Fig. S5B). The macrophage morphology
was not different in either cohort, suggesting no overt macro-
phage activation when Muc5ac was overexpressed (Fig. S5C).
These results, coupled with the absence of inflammatory cells in
histologic sections (Fig. S4B), indicate that mucin hypersecretion
alone does not initiate inflammation.
Muc5ac-GFP Organization and Localization in the Lungs. To test
whether transgenic Muc5ac-GFP was able to organize in a char-
acteristic gel-forming mucin network, i.e., mesh-like structure,
the extracellular Muc5ac-GFP was allowed to accumulate post-
mortem in a trachea tied off at its proximal end over a 2-h period
(Fig. 3A). The luminal contents of tracheal sections were ob-
served in situ under a confocal microscope to visualize the native
GFP organization. Transgenic animals displayed strong signals
depicting complex networks of interpenetrating GFP-positive
material, which resembles the entangled mesh of endogenous
mucus (14, 17).
Localization of cells expressing GFP fluorescence in freshly
excised or frozen sections was limited because of poor structural
preservation and/or a weakened GFP signal (as shown in Fig. S6).
Therefore, GFP immunohistochemistry was performed on fixed
tissue. It has been shown that immunohistochemistry is a sensitive
technique that can detect mucins in cells despite the lack of AB-
PAS staining (18, 19). Note that the reported distribution of
Muc5b-producing cells in WT mice, i.e., increasing numbers in
the proximal airways (18), correlated with our real-time PCR data
(Fig. 1D). Immunohistochemistry detected GFP-positive cells
throughout the airways of Muc5ac-Tg mice (Fig. 3B). Consistent
with previously published Clara cell distributions (15), large and
small airways both exhibited significant numbers of GFP-positive
cells. In rare cases, GFP-positive cells were also detected in al-
veolar regions (Fig. 3B and Fig. S6A). High-resolution images
revealed the presence of GFP-positive granules in dome-shape–
like cells, suggesting proper packaging of Muc5ac-GFP for mat-
uration and regulated secretion by Clara cells. In the large airways
of Muc5ac-Tg, but not of WT animals, the presence of an extra-
cellular GFP- orMuc5ac-positive layer was detected (Figs. S7 and
S8) and was further analyzed via electron microscopy.
Mucus Layer Depth and Effect on Mucociliary Clearance. Biophysical
modeling predicts that clearance rates will not be affected by
mucus layer heights as long as the mucus concentration remains
between 2% and 5% solid content (20). However, clearance
rates are impaired above 6% solids, and clearance ceases at
concentrations above 8% solids, i.e., in severe cases of de-
hydration. To test whether mucus clearance in vivo was affected
by the overproduction of Muc5ac, we measured rates of clear-
ance of fluorescent beads in tracheas of WT vs. Muc5ac-Tg mice
(Fig. 4A). Clearance rates were measured during deep anesthesia
and immediately after death because ciliary beat, and hence
clearance, continues several hours postmortem (21). No signifi-
cant differences in clearance rates were detected between the WT
(1.69 ± 0.10 mm/min, n = 13) and Muc5ac-Tg (1.49 ± 0.17 mm/
min, n = 11) animals, suggesting the presence of a sufficiently
hydrated mucus that is removed efficiently from the surfaces.
Thus, overexpression of Muc5ac is predicted, on the basis of these
data, to form an expanded, i.e., “taller,” mucus layer rather than a
hyperconcentrated layer.
To measure the depth of the mucus layer, we used osmium
perfluorocarbon to fix the lungs of WT and Muc5ac-Tg mice.
Lung sections were initially stained with Richardson’s reagent,
which revealed that a number of Muc5ac-Tg airways showed
evidence of a “thicker” mucus layer (Fig. S9). Airways of the
midsections of the lobes were randomly selected to be analyzed
via electron microscopy. Fig. 4B shows the presence of a mucus
layer of ∼2 μm in height lining the airways of Muc5ac-Tg animals
whereas WT airways showed sporadic mucus patches whose
depth did not exceed 0.5 μm. Statistical analysis revealed that an
average 1.4-μm mucus layer lined the airways of Muc5ac-Tg mice
vs. 0.2 μm in WT (Fig. 4C) (P < 0.0001); i.e., it was taller. Note
that despite the lack of AB-PAS staining in Muc5ac-Tg mice,
electron microscopy detected an increased number of electron-
Fig. 3. Muc5ac-GFP organization and protein expression. (A) Native
Muc5ac-GFP signal from freshly harvested lungs to demonstrate polymer
formation by the Muc5ac transgene, i.e., GFP meshwork in Tg animals.
Images show cross-sections of mouse trachea, tied proximally for 2 h post-
euthanasia to allow mucus to accumulate into the lumen (*). Arrow points at
the mucus blanket lining the airways of Tg animals. WT, wild-type control.
(B) Retrieved GFP signal from fixed lungs. Proximal and distal airway sections
from transgenic mice were stained with a polyclonal anti-GFP antibody and
DAPI, for nuclear stain. (Insets) Corresponding DIC/DAPI images are shown.
WT image are shown as a control.
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lucent granules characteristic of mucin-containing secretory gran-
ules (22) in dome-shape–like cells.
Resistance to Influenza PR8 Infection. The expanded mucus layer in
Muc5ac-Tg mice suggested that the protective function of the
mucus layer against inhaled pathogens and particulates may be
enhanced. Because secreted Muc5ac is highly sialylated and in-
fluenza virus infection requires binding of virus to sialic acid
residues in airway epithelia, we tested the hypothesis that in-
creased Muc5ac secretion may provide an enhanced mesh/ad-
hesive barrier that would prevent influenza viruses from gaining
access to the airway epithelium. In three different experiments,
WT and Muc5ac-Tg littermates from three separate litters were
inoculated via the nose with 700 plaque-forming units (pfu) of
a mouse-adapted influenza virus PR8 (A/PR/8/34 H1N1) and
infection was determined by measuring lung viral titers, using
standard plaque assays (Fig. 5A). Consistently, Muc5ac-Tg mice
exhibited significantly reduced viral loads in the lungs than
control mice at days 2 (7.0-fold) and 4 (9.3-fold) postinoculation
(p.i.). To determine whether infection-induced inflammation was
also reduced in Muc5ac-Tg vs. WT animals, inflammatory cells
were obtained from BALF and quantitated at day 2 p.i. (Fig. 5B).
The total number of macrophages was increased approximately
4-fold after PR8 infection similarly for both genotypes. However,
the number of BAL neutrophils was consistently decreased in
Muc5ac-Tg animals, with an average 3-fold fewer neutrophils
collected in Muc5ac-Tg BALF. These data indicate that Muc5ac
overexpression serves as a protective barrier against influenza
virus infection in vivo.
Infectivity of Influenza PR8 in Vitro Altered by Muc5ac. To distin-
guish whether Muc5ac protein provides (i) a physical (mesh-like)
filtration barrier to influenza virus infection and/or (ii) an affinity
barrier by virtue of the terminal sialic acids on Muc5ac acting as
a decoy receptor, PR8 (100 or 1,000 pfu) was incubated in BALF
(with endogenous mucins diluted at least 25-fold) from WT and
Muc5ac-Tg mice. Infectivity was measured with Madin–Darby
canine kidney (MDCK) cells (Fig. 6A), and PBS containing BSA
at equal protein concentrations was used as a control. Muc5ac-
Tg BALF significantly reduced the number of plaques by 1.7-
and 1.8-fold compared with WT BALFs, respectively (P < 0.05).
A BALF contains a mixture of mucins, including Muc5b, and
other natural defense molecules, limiting the ability to isolate the
role of Muc5ac in viral neutralization. Accordingly, purified
Muc5ac was prepared at a concentration similar to that in vivo
(2 mg/mL) and was tested for protection against viral infection.
Muc5ac exhibited a 2.2-fold inhibitory effect on viral infectivity
at 100 pfu tested, supporting the notion that Muc5ac alone is
able to protect against viral infection (Fig. 6B).
Influenza virus receptor specificity for airway epithelia is de-
termined by cell surface terminal sialic acid linkages of the glycan
chain that occur via carbon 3 or carbon 6, generating two distinct
conformers: α2,3- and α2,6-linked sialic acids. It has been reported
that PR8 preferentially binds to α2,3-linked sialic acids (23, 24),
which are the most abundant conformer found on the surface of
the avian digestive tract (25), but are not the predominant con-
former in human lungs (26). Because Muc5ac reduced viral in-
fectivity by an apparent binding mechanism, we investigated
whether binding may reflect preferential expression of the α2,3-
sialic acid conformer on murine Muc5ac protein. Lectin binding
assays and Western blotting on Muc5ac-Tg BALF demonstrated
that α2,3-, but not α2,6-linked, sialic acids colocalized with the
Muc5ac-GFP signal (Fig. 6C). Note that neither lectin appeared to
bind to the upper region of the gel where the Muc5b signal typi-
cally occurs in mouse BALF (Fig. 3). The removal of the sialic
acids in Muc5ac-Tg BALF by treatment with neuraminidase re-
stored PR8 infectivity in vitro, consistent with an important role of
sialic acids inMuc5ac protection for PR8 infection (Fig. S10). This
finding supports the notion that PR8 infection is reduced in
Muc5ac-Tg animals at least in part from biochemical competition
for PR8 binding by Muc5ac vs. surface α2,3-sialic acid receptors.
Discussion
Mucins are secreted onto surfaces that are exposed to external
pathogens, e.g., the respiratory, digestive, and reproductive tracts.
Mucins have long been regarded as exerting a role as a barrier to
prevent mucosal infection but data supporting this notion are few
(27, 28). One of the main reasons for the absence of such data is
the lack of biochemical tools to study these large and complex
molecules in intact biological systems. The complexity of these
high-molecular-weight glycoproteins resides in their size and the
numerous domains distributed throughout themolecule, including
the von Willebrand domains, the cysteine-rich regions, and the
VNTRs. Indeed, the genomic region encoding for Muc5ac is 29
kb, including 49 exons, and is predicted to produce a 9-kb RNA
transcript. The highly homologous tandem repeat units are located
in the central region flanked by two identical non-VNTR sequences,
which causes this region to be difficult to clone and/or sequence.
Hence, molecular manipulations of mucins are challenging, and
biochemical reagents and assays available to study these mole-
cules are limited.
Fig. 4. Clearance rates and depth of the mucus layer. (A) Mucociliary
clearance rates were measured by monitoring the transport of fluorescent
beads across the trachea for WT (n = 13) and Tg (n = 11); P = 0.07. (B) WT and
Tg lungs were fixed with perfluorocarbon-OsO4 to preserve the mucus layer
(arrows) and observed with transmission electron microscope. (Scale bar,
2 μm.) (C) The graph shows the statistical analysis of the mucus layer depth
revealed by EM images from 3 WT and 3 Tg animals; *P < 0.0001.
Fig. 5. Lung virus titers and inflammatory cell count following influenza
infection. WT and Muc5ac-Tg mice were infected with 700 pfu of PR8 via
intranasal instillation. Weight loss was monitored daily and did not exceed
25% for either group. (A) Mice were euthanized either at day 2 (n = 5 for
each line) or at day 4 (n = 4 for each line) postinfection. Lung homogenates
were analyzed by standard plaque assay for virus titers. Values are means ±
SEM; *P < 0.05, **P < 0.001. (B) Mouse lungs (n = 5 for each line) were
lavaged at day 2 postinfection and analyzed for inflammatory cell pop-
ulations. Values are means ± SEM; *P = 0.014.








Partial cloning of the MUC5AC cDNA, mainly of the 5′ and 3′
ends, was achieved in the past, primarily to study domain ho-
mology (29, 30) and explore domain interactions (31). The
cloning and tagging of the full-length Muc5ac cDNA as reported
here provide a unique biological tool to study and/or monitor
mucin in its physiologic environment and facilitate purification.
We achieved an approximate 20-fold increase in Muc5ac ex-
pression in murine large and small airways (Fig. 1D). It has been
believed that mucins may exhibit reciprocal compensatory reg-
ulation and influence the expression of other mucins (32, 33).
However, in Muc5ac-Tg mice, Muc5b expression was unaffected,
suggesting that the expression of Muc5ac and Muc5b can be
independently regulated in the absence of disease.
Muc5ac overexpression in transgenic mice was confirmed at the
protein level (Fig. 2C). Several Muc5ac peptides distributed
throughout the molecule were used to immunize rabbits but mucin
antibodies are notoriously difficult to develop. Posttranslational
modifications heighten the antigenic complexity of Muc5ac, e.g.,
the extensive O-glycosylation of the VNTR region, disulfide
bonding, and dimer formation via cysteine residues. Upon exo-
cytosis, mucin monomers form massive aggregates with molecular
masses of roughly 1–10 million Da. The complex secondary
structure and large carbohydrate backbone prevent mucins from
migrating on traditional polyacrylamide gels and can impede an-
tibody access to the mucin protein core. However, antibody
UNC294 was able to detect Muc5ac in its reduced form in agarose
gels (Fig. 2B). This antibody revealed a 17.7-fold increasedMuc5ac
secretion in BALs of transgenic animals compared with WT and
approximately 2-fold over the OVA-challenged model (Fig. 2C).
Several mouse models have been engineered to study the role
of mucin secretion but most of these models do not exhibit in-
creased expression of a single mucin (34–36). The only pure gain-
of-function model published to date is the Muc1 transgenic
mouse that overexpressed the human MUC1 cDNA and was
generated to investigate immunotherapy targets for breast cancer
(37). Although the ovalbumin-challenged mouse is viewed as
a mucin-overproducing model with goblet cell hyper/metaplasia,
it exhibits up-regulation of multiple mucins and cannot be studied
separately from the airway hyperresponsiveness and eosinophilia
(38). The βENaC-overexpressing mouse is another model that
develops a mucin hypersecretion phenotype with airway mucus
plugging and goblet cell hyperplasia (14). However, this model
again exhibits complex regulation of mucins and also exhibits
neutrophilic inflammation, making it difficult to establish whether
mucus overproduction triggered the neutrophilic response or vice
versa. The Muc5ac-Tg mouse is a unique model to unequivocally
test the relationship between mucin hypersecretion, airways ob-
struction, and inflammation. Muc5ac hypersecretion of ∼20-fold
overWT levels produced (i) no evidence of airways obstruction in
the small airways, despite an approximate 10-fold increase in total
mucin expression, or in the large airways with an approximate
2-fold increase in total mucin expression, and (ii) no evidence of
inflammation (Fig. S5).
Although Muc5ac-Tg Clara cells produced more Muc5ac and
showed evidence of mucin granules via EM (Fig. 4 and Fig. S9),
these cells did not stain with AB-PAS or adopt a metaplastic or
enlarged goblet cell appearance (Fig. 3). These observations
suggest that AB-PAS staining may detect static aspects of mucin-
secreting cells, staining preferentially mucins that are stored in
granules, but does not reflect mucin turnover. In normal con-
ditions, some mucins, e.g., Muc5b in murine airway surfaces, may
be continuously produced, secreted, and transported without
a large storage pool (18). BecauseMuc5ac-Tgmice secretedmore
Muc5ac-Tg mucin without an apparent increase in goblet cell
number or goblet cell metaplasia, it appears likely that Muc5ac-
Tg mucins are secreted from Clara cells without a metaplastic
change that produced AB-PAS–positive storage granules.
The Muc5ac-Tg model showed that increased secreted mucin
could be cleared from airway surfaces without accumulation or
plugging. Our morphological data suggest that the approximate
doubling of mucus (equivalent volume of Muc5ac and Muc5b)
on proximal airway surfaces is handled by increasing the height
of mucus layer, with presumably no change in concentration,
rather than maintaining the same height but increasing the
concentration (Fig. 4 B and C). These data are consistent with
MCC data that revealed that MCC rates are comparable in WT
and in Muc5ac-Tg animals (Fig. 4A). Note that recent data
suggest that a doubling of mucin concentration would be asso-
ciated with slowed MCC (20).
The Muc5ac-Tg model demonstrates that Muc5ac acts as
a protective barrier against a specific influenza strain infection.
Previous studies have suggested that mammalian viruses have
evolved mechanisms to facilitate their penetration through the
mucus barrier (39). Muc5ac-Tg mice were more resistant to PR8/
H1N1 influenza in vivo, and incubation of PR8 with the purified
mucin reduced the rate of infection in vitro, which suggests a di-
rect “antiviral” effect of Muc5ac (Figs. 5A and 6A). Interestingly,
the Muc5ac-GFP glycoprotein expresses terminal α2,3-sialic
acids, the identified receptor for PR8 (Fig. 6A). Thus, we specu-
late that the increased Muc5ac with its sialic acid residues pro-
tected Muc5ac-Tg mice against specific influenza infections by
acting as a “decoy” to bind virus in a mobile phase. This action
prevented access of the virus to the airways surfaces, a necessary
process to mediate cell infection.
Mucins may vary across species by expressing different sialic
acid linkages that protect against viral infection. This notion is
supported by the fact that α2,6-linked sialic acids, the preferred
receptors for human influenza viruses, have been associated with
mucins expressed in the human lung (40). Here, we have shown
that α2,3-linked sialic acids, the preferred receptors for murine
viruses, are associated with a secreted mucin (i.e., Muc5ac) in the
murine lung. In addition, we have demonstrated that Muc5ac in-
dependently of its physical barrier role, i.e., in solution, and in
Fig. 6. Plaque reduction and lectin-binding assays. (A) MDCK cells were infected by mixing 100 or 1,000 PR8 pfu (or 103 or 104 pfu/mL solution), as indicated,
with BSA, WT, or Mu5ac-Tg BALF (1 mg/mL) and plaque number was quantitated. (B) Muc5ac was purified from Muc5ac-Tg BALF, using denaturing agents
and a density gradient. MDCK cells were infected by mixing 100 PR8 pfu (or 103 pfu/mL solution) with BSA or purified Muc5ac (2 mg/mL). Values are means ±
SEM; *P < 0.05, **P < 0.001 (n = 3). (C) Western blots from a Muc5ac-Tg BALF were coimmunostained with a GFP antibody (in green) and α2,3- or α2,6-sialic
acid-binding lectins (in red) to identify the sialic acid linkage for Muc5ac. Independent channels are shown in black and white.
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absence of other defense molecules, i.e., purified Muc5ac, was able
to protect against PR8 influenza infection (Fig. 6A), which reveals
an “anti-infectivity” role per se for Muc5ac. Moreover, whether it is
a direct result of the anti-infectivity role or an “anti-inflammatory”
role of mucin, the neutrophilic response was reduced in Muc5ac-
Tg mice after infection, which may provide an additional protective
benefit to the lungs by limiting tissue damage (Fig. 5B).
Although mucin hypersecretion is perceived to contribute to
morbidity and mortality in airway obstructive diseases, “mucor-
egulatory” therapy is infrequently used in patients with asthma,
bronchitis, COPD, or cystic fibrosis, mostly because of its in-
efficiency. Importantly, the Muc5ac-Tg model supports the idea
that increased mucus production might not be the primary cause
for airway obstruction and, hence, a disease target. Therefore,
the use of antisecretory therapies for preventive purposes may
compromise the protective role of mucins, a concept supported
by data from tethered mucin-deficient mice. Muc1-deficient mice
are less resistant to Helicobacter pylori colonization than control
littermates and develop a severe subsequent gastritis (41). Muc2-
deficient mice spontaneously develop colitis (35) and have im-
paired resistance against enteric infection (42).
In conclusion, Muc5ac-Tg mice secrete ∼20 times more
Muc5ac into their lungs, which leads to an expanded mucus layer
lining the airway surfaces. The excess mucus is efficiently cleared
from the lungs, demonstrating that mucin overproduction can
occur without airways obstruction or airways inflammation. Re-
sistance to PR8 influenza infection in mice overexpressing Muc5ac
was increased as a result of, at least in part, biochemical compe-
tition for the viruses that bind to sialic acids decorating Muc5ac
rather than receptors on cell surfaces. Therefore, future thera-
peutics aimed at reducing mucin production with the purpose of
ameliorating airway obstruction may require careful titration to
not compromise host defense.
Materials and Methods
The full methods and additional analysis and data are provided in SI Materials
and Methods.
mRNAs were extracted from C57BL/6J mouse lungs and Muc5ac cDNA was
internally tagged with GFP. Gene expression was measured by quantitative
PCR. Bronchoalveolar lavages were performed to collect fluid and quantify
mucin and lung inflammatory cells as previously described (18). The rate of
mucociliary clearance was determined by measuring the movement of
fluorescent beads along the trachea (21). Mice were inoculated via an in-
tranasal route with the influenza virus A/PR/8/34 (H1N1) and virus titers were
determined by standard plaque assays on MDCK cells.
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